Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment

Anti-VEGF antibody bevacizumab has prolonged progression-free survival in several cancer types, however acquired resistance is common. Adaption has been observed pre-clinically, but no human study has shown timing and genes involved, enabling formulation of new clinical paradigms. In a window-of-opp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Shaveta, Hughes, Nick P., Li, Sonia, Jubb, Adrian, Adams, Rosie, Lord, Simon, Koumakis, Lefteris, van Stiphout, Ruud, Padhani, Anwar, Makris, Andreas, Buffa, Francesca M., Harris, Adrian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006694/
https://www.ncbi.nlm.nih.gov/pubmed/27474395
http://dx.doi.org/10.1016/j.ebiom.2016.07.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006694/
https://www.ncbi.nlm.nih.gov/pubmed/27474395
http://dx.doi.org/10.1016/j.ebiom.2016.07.017

Ejemplares similares